Current studies involving cellular models or disease confront two challenges: recapitulate what happens in the human body, and access longitudinal information. These challenges, which often limit the accuracy and value of cellular models, are being addressed by ExpressCells, a company that has developed a new gene modification technology to expedite the production of custom, knock-in cell lines."When disease models use conventional gene reporter systems, researchers can see whether a protein is promoted, activated, or inhibited, but the model may not accurately replicate what actually happens in the human body," explains ExpressCells CEO Matthew Handel. "Fixing and staining cells to study endogenous protein targets is another option, but then information isn't longitudinal. Fixed cells show only snapshots in time."
展开▼
机译：涉及细胞模型或疾病的目前的研究面对两个挑战：概括了人体发生的事情，并获得纵向信息。 这些挑战通常限制了蜂窝模型的准确性和价值，该挑战是通过Expresscell的提出，该挑战是由Expresscells的旨在开发出一种新的基因改性技术，以加快生产习俗，敲入细胞系。“当疾病模型使用常规基因时 记者系统，研究人员可以看出蛋白质是否促进，激活或抑制，但模型可能无法准确地复制人体实际发生的内容，“Expresscells Ceo Matthew Handel解释说。 “用于研究内源蛋白靶标的固定和染色细胞是另一种选择，但随后信息不是纵向的。固定单元仅显示快照。”
展开▼
